|Titre :||Drugs strategies and action plans in the European Union 2000-2004. Contribution to the evaluation of the EU action plan on drugs (2000-2004)|
|Auteurs :||OEDT = EMCDDA|
|Type de document :||Rapport|
|Editeur :||Lisbon : OEDT / EMCDDA, 2004|
|Format :||12 p.|
|Discipline :||PRE (Prévention / Prevention)|
Thésaurus TOXIBASEEVALUATION ; PLANIFICATION SANITAIRE ; POLITIQUE
Thésaurus GéographiqueEUROPE ; UNION EUROPEENNE
Since the late 1990s, drug strategies and action plans have been increasingly adopted by EU countries as the central instrument for implementing drug policy. This thematic paper looks at the origins and characteristics of this phenomenon as well as recent trends and perspectives for future development.
The need for governments to address the drug problem through the adoption a national drug strategy was first tabled by the United Nations in 1987 and was reaffirmed by the 1998 UN General Assembly Special Session on Drugs (UNGASS). The EU strategy and action plan reiterate this principle, endorsing the idea of a 'national coordinated balanced drug strategy'. In 2003, a European Commission 'Communication on coordination on drugs in the European Union', directly asked Member States to adopt a comprehensive national strategy or action plan on drugs. Almost all EU countries now report to have done so.
Across Member States, the 'drug strategy' may take many forms (e.g. drug programme, national strategy, action plan, plans of intervention, policy note). Differences are not only found in designation but also in time-span and goals. However common themes are found (e.g. treatment, harm reduction, supply reduction, coordination, etc.) and key elements (e.g. evaluation, 'global approach', prevention) can be traced back to the EU strategy.
This paper defines a drug strategy as a set of general principles, priorities and objectives giving direction to government drug policy, while an action plan sets out the precise targets, resources and timescale for achievement. It proposes that these definitions be clarified during the drafting of the new EU strategy and action plan, that common standards be drawn up to ensure consistency between drug policies of 25 EU countries and that activities and methodologies be promoted to mobilise resources for evaluation. The issue of consistency between an overall EU drug strategy, subsequent EU plans of action, and 25 national strategies and plans could be reflected on in a collegial manner by the EU, its says.
|Domaine :||Drogues illicites / Illicit drugs|
|Affiliation :||EMCDDA 'Strategies and Impact' Programme, Lisbon, Portugal|
|Titre précédent :|
|Titre suivant :|
Documents numériques (1)
Adobe Acrobat PDF